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Abstract
Background: While the public health benefits of new HCV treatments depend on treatment adherence, particularly
among people who inject drugs (PWID), several social and medical factors can jeopardize treatment adherence. The
aim of this study is to examine the qualitative literature on facilitators to HCV treatment adherence among PWID.
Methods: We searched six databases to identify qualitative research studies on HCV treatment adherence
facilitators among PWID. Two reviewers independently extracted and analyzed data using PRISMA guidelines and
the CASP tool to evaluate study quality.
Results: From ten studies representing data from 525 participants, three major themes emerged across studies:
logistical facilitators within health systems enhanced HCV treatment adherence, positive social interactions between
PWID and staff provided positive feedback during treatment, and HCV treatment may complicate the addiction
recovery process.
Conclusions: Although PWID face several barriers to adherence, we identified treatment adherence facilitators that
could be incorporated into clinical practice.
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Background
Hepatitis C virus (HCV) remains a significant cause of
morbidity and mortality, affecting over 130 million
people worldwide [1]. HCV is estimated to be respon-
sible for roughly one quarter of all cases of hepatocellu-
lar carcinoma and cirrhosis, [2] and mortality from
HCV-related liver disease has surpassed mortality from
HIV in the United States [3]. HCV is more commonly
transmitted through blood transfusions and iatrogeni-
cally in developing countries, and through intravenous
drug use (IVDU) in developed countries, though this re-
mains an issue in developing countries as well [4]. In
general, the burden of HCV infection falls dispropor-
tionately on people who currently inject or have injected
drugs in the past (PWID), with HCV antibodies reported
in greater than 60 % of PWID in 37 of 77 geographically
and economically dispersed countries [5]. Unfortunately,
PWID are frequently excluded from treatment due to
concerns about adherence, concurrent drug use, psycho-
social comorbidities and the higher risk of reinfection
secondary to active drug use [6, 7]. Studies have shown
that the likelihood of achieving sustained virological re-
sponse (SVR) is much higher when patients are adherent
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to treatment, [8] and that there is little difference in
SVR rates between PWID and others [9]. While prior re-
search has focused on facilitators to testing and initiating
treatment among PWID, [10] little is known about facili-
tators that specifically help this vulnerable population
achieve high levels of adherence.
For decades, interferon-based therapy has been the
standard of care for HCV, most popularly a regimen of
pegylated interferon and ribavirin (pegIFN + RBV). How-
ever, long treatment courses, hematologic and psychiatric
side effects, and the uncertainty of achieving SVR com-
plicate interferon-based treatment for many patients
and providers [11, 12]. Even for patients who pass
screening for treatment, implementation can be chal-
lenging. The HCV care continuum involves multiple
steps—serologic testing, radiographic imaging, possible
biopsy, attendance at multiple follow-up visits, and ad-
herence to a demanding treatment regimen [13]. Minor
setbacks, both physiological, such as difficult to handle
side effects, and non-physiological such as logistical dif-
ficulties, at any point may jeopardize the success of
treatment.
Recent advances in the treatment of HCV in the form
of direct acting antivirals (DAAs) will broaden treatment
eligibility and options. DAAs may be used in conjunc-
tion with pegIFN + RBV, but interferon-free DAA regi-
mens have reduced side effect profiles while still
achieving SVR rates as high as 90 % with a shorter treat-
ment duration: 8–12 weeks compared to several months
with interferon therapy [13–15]. All of these factors help
make treatment more tolerable, especially among pa-
tients with comorbid mental health disease or substance
abuse issues [16]. In the United States and other high-
income countries, treatment with DAAs is now the
standard of care, though the high cost (over $100,000
USD per treatment course in the United States) presents a
significant barrier in low- and middle-income countries
(LMIC) [4]. Likely reflecting the difficulties in global ac-
cess to DAA, the WHO’s guidelines for management of
hepatitis C released in 2014 continued to prioritize
pegIFN + RBV treatments worldwide [13]. However, as
DAAs become the standard of treatment, both their long-
term success and avoidance of drug resistance will hinge
on achieving high levels of adherence [17]. Given the dis-
proportionately high burden of disease among PWIDs, it
is imperative that they are included in DAA scale-up pro-
grams and achieve high levels of adherence [18].
Qualitative data provide an important perspective on
adherence for three reasons. First, adherence may dir-
ectly depend on social factors that are not captured in
quantitative studies. Second, qualitative data can provide
rich information about values, preferences, and implica-
tions for human rights that are not included within ran-
domized controlled trials. Finally, qualitative reviews of
adherence in tuberculosis [19] HIV [20] and other dis-
eases [21, 22] have provided useful information. The
purpose of this systematic review is to evaluate qualita-
tive studies investigating facilitators to HCV treatment
adherence among PWID.
Methods
The protocol for this study was registered on PROSPERO,
the International Prospective Register of Systematic
Reviews (CRD42013006057).
Search strategy and selection criteria
Six electronic databases (CINAHL, ACS, MEDLINE,
EMBASE, PSYCInfo, PubMed) were searched for cita-
tions related to treatment adherence in HCV-positive
PWID. More detail on the search algorithm is included
in Additional file 1. Studies were included if they were
qualitative, written in the English language, and pub-
lished in a peer-reviewed journal. We followed guidance
from PRISMA [23].
Qualitative methods accepted included in-depth inter-
views, focus groups, personal narratives, and mixed
method studies. The search was initially completed
February 20, 2014 and updated last on October 27,
2015. Studies on current and former injection drug users
with HCV, including those in methadone treatment,
were included. While our study focused on HCV medi-
cation adherence, qualitative reviews also covering HCV
linkage and retention in care were included if relevant.
Studies dealing with HIV/HCV co-infected patients were
included, if applicable. Titles and abstracts were evalu-
ated for relevance by a single independent reviewer. Full
texts were evaluated by two independent reviewers. Dis-
crepancies were brought to a third independent reviewer
for discussion and resolution. Detailed study screening
methods and a search flow diagram according to
PRISMA guidelines are included (Fig. 1).
Analysis and synthesis
The objective of this meta-synthesis was to identify facil-
itators to HCV treatment adherence among HCV-
infected PWID. We utilized the Noblit and Hare [24]
meta-ethnographic approach that has been widely used
for other medical qualitative systematic reviews [25].
Findings from one citation were compared with findings
from another paper through reciprocal translation then
condensed to create thematic structures. Each paper was
systematically reviewed by two authors for missing data
and data not encompassed in the thematic structures.
Themes were then used to summarize facilitators of
HCV adherence among injection drug users. Participant
identifiers were included in the results when they were
present in the primary data.
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Study appraisal
After a final list of full text articles was obtained, three
authors (ZCR, CC and JM) independently reviewed all
included studies and assessed them for completeness
using the Consolidated Criteria for Reporting Qualitative
Research (COREQ) checklist [26], a standardized and
way to evaluate qualitative research studies. Included
studies were then evaluated using the Critical Appraisal
Skills Programme (CASP) tool (Table 1).
Results
Our search yielded a total of 595 citations of which ten
met inclusion criteria. Figure 1 details the exclusion of
papers at each stage of the screening process.
Description of studies
All ten studies were conducted in high-income, Western
countries. One study examined adherence to interferon
only, [27] eight studies examined interferon and ribavirin
regimens [10, 12, 28–33] and one study examined DAA
triple therapy adherence [34]. A description of these
studies can be found in Table 2. These studies represent
data from 525 participants and were conducted through
in-depth interviews, [10, 12, 27–30, 32–34] focus groups,
[12, 30, 32] and personal narratives [31]. The number of
participants in each study ranged from 2 to 164.
Description of the themes
The emergent themes are shown in Table 3. We identi-
fied three overarching final themes: logistical support for
patients; positive interactions with support staff; and un-
derstanding the drug user identity.
Theme one: logistical support for patients
Many patients expressed that their complex financial
and medical needs must concurrently be accounted for
in order to maintain high levels of adherence. This
theme included facilitators both outside of the health
Fig. 1 Flowchart demonstrating search strategy
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Table 1 Quality assessment of included research studies
First Author (Year) Is the study
qualitative
research?
Is the study
context clearly
described?
Is there evidence
of researcher
reflexivity?
Is the sampling method
clearly described and
appropriate for the
research question?
Is the method of data
collection clearly described
and appropriate to the
research question?
Is the method of analysis
clearly described and
appropriate to the
research question?
Are the claims made
supported by sufficient
evidence? i.e., did the
data provide sufficient
depth, detail, and
richness?
Total
Harris (2009) [47] 1 1 1 1 1 0 1 6
Harris (2013) [35] 1 1 1 1 1 1 1 7
Hopwood (2007) [29] 1 1 1 1 1 1 1 7
Munoz Plaza (2008) [30] 1 1 1 1 1 1 1 7
Nguyen (2007) [31] 1 1 0 1 1 0 1 5
Norman (2008) [32] 1 1 1 1 1 1 1 7
Strauss (2005) [12] 1 1 1 1 1 1 1 7
Treloar (2008) [27] 1 1 1 1 1 1 1 7
Treloar (2013) [33] 1 1 1 1 1 1 1 7
Rasi (2014) [34] 1 1 1 1 1 1 1 7
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services (such as transportation and job assistance) and
within the healthcare system (flexible clinic hours and
integration of services).
Support outside the healthcare system: “I wouldn’t think of
doing this if I was out on the street”
Transportation was mentioned frequently among patients
as a critical mediator of adherence [32, 35–37]. Two
studies provided transportation assistance for HCV-
infected PWID to HCV clinical services (Additional file 2,
Row1) [31, 32].
“Well partly the transport [is a barrier], but I think it’s
a psychological thing for a lot of our patients, they’re
very entrenched in their own environment…. You tell
them that you’ve got an appointment at [hospital
Table 3 Initial concepts, emerging themes, and final themes related to HCV treatment adherence facilitators
Initial concept Relevant papers Emerging themes Final themes
Shelter assistance Strauss 2005 Support outside the clinic Logistical support for
patients
Transportation assistance Harris 2013, Norman 2008,
Rasi 2014
Integration of services Norman 2008, Strauss 2005,
Harris 2013, Treloar 2013
Accommodating clinic
Flexible appointment times Rasi 2014
Accommodating phlebotomy services Harris 2013
Kind and attentive care Harris 2013, Norman 2008,
Strauss 2005, Treloar 2013,
Rasi 2014
Compassionate clinical staff Positive interactions with
support system
Peers who understand addiction Norman 2008, Strauss 2005 Support of current and former
injection drug users
Examples of treatment success Munoz-Plaza 2008,
Treloar 2013
Avoid needles that trigger relapse Harris 2009, Nguyen 2007 Help avoiding substance abuse
relapse
Understanding drug user
identity
Managing side effects that mimic withdrawal Harris 2009, Strauss 2005
Improving health to care for others Treloar 2013
Table 2 Manuscripts included in qualitative evidence review (n = 814 individuals in 18 studies)
First author Year Location Study design Sample size (n) Sample population Treatment methods
Harris 2009 Australia Interviewsa 40 Former PWID seeking care Interferon + ribavirin
Harris 2013 United Kingdom Interviews 49 Current and former PWID
and providers
Interferon + ribavirin
Hopwood 2007 Australia Interviews 20 Patients and providers from
a HCV treatment center
Interferon-based, unspecific
Munoz Plaza 2008 USA Interview,
Focus groups
164 Patients enrolled in drug
treatment programs
Interferon + ribavirin
(not all patients on treatment)
Nguyen 2007 Australia Personal narratives 3 Patients enrolled in PEG-IFN
treatment study
Interferon OR interferon +
ribavirin if HIV/HCV co-inf
Norman 2008 Australia Interviews,
Focus groups
10 Current or former PWID
seeking care or working at
HCV treatment center
Interferon + ribavirin
Strauss 2005 USA Interviews,
Focus groups
72 Patients and staff in a drug
treatment programs
Interferon + ribavirin
Treloar 2008 Australia Interviews 77 Current and former drug
treatment patients
Interferon only (n = 2)
Treloar 2013 Australia Interviews 76 HCV patients receiving opiate-
substitution treatment
Interferon + ribavirin
Rasi 2014 Switzerland Interviews 14 HCV patients undergoing
protease-inhibitor therapy
DAA triple therapy (Protease
inhibitor, interferon, ribavirin)
Abbreviations: PWID people who inject drugs, HCV hepatitis C virus, PEG-IFN pegylated interferon
aInterviews refer to one-on-one, in-depth interviews
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name], well you might as well say it’s in Timbuktu
because they have no idea where that is” [35].
In addition to the physical act of getting a patient to
their appointment, transportation services may be help-
ful for guiding patients to an unfamiliar treatment center
(Additional file 2, R1) [35].
Additionally, services that provided long-term housing
for patients undergoing treatment helped patients toler-
ate the side effects of interferon therapy, as lack of stable
environment was cited as a barrier to remaining adher-
ent to treatment (Additional file 2, Row2) [38].
For homeless patients, having access to shelter services
following the weekly interferon injections was seen as
necessary for treatment completion (Additional file 2,
Row3) [12].
“I wouldn’t think of doing this if I was out on the
street… I mean, I used to be in the bed after taking
that stuff, just shaking… I would never been able to go
through that out on the street” [12].
Accommodating clinic: “My needs are met in a whole lot of
different ways, from personal to support, to my addiction
to ramifications from the addiction”
Many participants highlighted logistical factors within
the clinic that facilitated their ongoing treatment. Para-
mount among these was the integration of HCV ser-
vices with other services that are commonly sought by
PWID such as addiction specialists, mental health ser-
vices, and other general medical services (Additional
file 2, Row4) [32].
“My needs are met in a whole lot of different ways,
from personal to support, to my addiction to
ramifications from the addiction” [32].
This integration of services was seen as “making it eas-
ier” not having to “run around” [32]. Several studies
commented on improving adherence through HCV
treatment integration with inpatient [12, 37] or out-
patient drug rehabilitation programs [32, 35, 38]. Pa-
tients often felt more comfortable receiving HCV
treatment at drug treatment centers where they were
less worried about treatment-associated stigma [33].
However, others were worried that receiving integrated
services may threaten confidentiality, [33] though ac-
counts of this happening were not reported in any study.
Participants also identified flexible clinic hours for re-
ceiving treatment, testing, or other services as another
mediator of adherence [34]. This was seen as particularly
true for patients with ongoing substance use.
Lastly, patients identified the importance of more
accessible phlebotomy services. Patients felt that more
convenient hours and well-trained, non-judgmental
phlebotomists would improve their outlook on continu-
ing with their treatment regimens [10].
“I kept on saying to [hospital phlebotomist], ‘Look, you
know, my veins are a nightmare, you know, let me do
it’. [She said] ‘Oh you people, you think you know
about your veins and all that, when you know
nothing” [35].
Theme two: positive interactions with support system
Many studies referenced patients’ perceptions of their
support systems, including attitudes from clinical staff as
well as formal or informal support groups, such as other
PWID.
Compassionate providers: “with this type of support I could
continue taking this drug”
Both patients and providers noted that positive patient-
provider relationships promoted treatment adherence
[12, 29, 32, 37, 39] (Additional file 2, Row7) Providers
who expressed concern and understanding gained the
trust of patients to withstand treatment and made the
side effects of the interferon more manageable [12, 35].
“About 4 or 5 months in the program, I started taking
the interferon. The people were very attentive to me;
the nurses were great—with this type of support I
could continue taking this drug” [12].
Clinical staff familiar with PWID were preferable to
general staff, particularly because of perceptions of re-
spect between the patient and the staff [29, 37].
“Just the people here. You can talk to ‘em a lot better.
They don’t look down on you. They actually talk to
you. They explain every- thing. You go to places, other
places, you know, yeah, they don’t make you feel very
welcome” [33].
Support of current and former injection drug users: “if we
didn’t have the peer support worker this program wouldn't
be running”
In one study, a peer counselor model was critical in
providing support throughout the treatment process
[32]. Peer counselors were seen as understanding and ap-
proachable, and they served as cultural ambassadors be-
tween doctors and patients (Additional file 2, Row8) [32].
“I think she has made the difference between sticking
to this or not…I have had more times where I have
thought ‘[expletive] this, I’m not doing this anymore,
go shove it up your [expletive]’ but if she wasn’t here
there would have been many more times. [I]f we didn’t
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have the peer support worker this program wouldn’t be
running” [32].
Peers served as examples of patients who had success-
fully undergone treatment and cleared HCV [30, 39].
Having a shared experience with other PWID supported
patients through treatment. This was true for both orga-
nized support groups [32] and informal relationships
[12]. Support groups, counseling sessions, and family
support gave patients the opportunity to disclose drug
use and treatment experience openly. In one study, a
methadone client on HCV treatment described how
important it was for her to know that “you’re not alone
in this. Love and concern is here, and that plays a major
part” [12].
Patients expressed desire to talk specifically with peers
with first-hand experience with treatment, [30] finding a
positive source of support in sharing challenges and suc-
cesses. They felt that the more they learned about their
disease from peers or providers, the more likely they
were to continue with their HCV treatment [32].
Theme three: understanding drug user identity
Avoiding relapse and managing ongoing drug use
Patients often stated that their first priority was to
remain sober and that any treatment for HCV would
have to be secondary to this goal. HCV treatment may
complicate the recovery process for PWID concurrently
engaged in addiction recovery [12, 40]. Patients may
need to interrupt their attendance at addiction services
and counseling, or physically leave a detoxification or
rehabilitation setting to attend clinic appointments
[12]. HCV treatment itself has been attributed to drug
relapse due to the complex constellation of side effects
of interferon treatment on mental health, further com-
pounded by alcohol, drug use, and substitution phar-
macotherapies [35, 41, 42].
“The depression kicks in, and you are bed-ridden. It is
hard enough just staying clean without it [HCV
treatment]. That is the scary part” [28].
Others noted that the side effects resembled opioid
withdrawal [28, 41].
“All my joints ached. I was in a sweat. I felt like I was
hanging out [withdrawing from heroin]. I felt like I’d
had a dirty hit…. I did think ‘a shot [of heroin] would
make me feel better’” [28].
Patients also stated that the act of injecting interferon
was itself addicting [31] and acted as a “trigger” for
wanting to use again (Additional file 2, Row9) [28].
Some facilitators mentioned were use of alternative
interferon delivery devices that minimized resemblance
to injecting heroin [28] and medications such as canna-
bis to minimize withdrawal like side effects of interferon
(Additional file 2, Row11) [29].
“Quite a few patients smoke cannabis … for relief of
nausea, to help them sleep, to help with aches and
pains, to help them relax. So, if they continue to do
that, that’s fine. I just ask them to tell me how much
they’re doing… because it can impact on mood” [29].
For current PWID, clinic policies that did not insist on
complete sobriety were a facilitator to treatment.
“We’ve got one guy, he injects probably once a week and
he comes for his appointments… he’s not trying to work
towards not using, that’s just part of his life. I think it is
important that people like him manage to access
treatment, that it’s not an exclusion criteria” [29].
Aspiring for new healthier identity: “on a good day I’m
gonna feel like really brilliant”
Some studies identified that although some patients did
not care for their own health, they would complete treat-
ment for the sake of others [33].
HCV treatment was also seen by PWID as an oppor-
tunity to create a new image for themselves. Many pa-
tients saw HCV infection as a drug-related problem, and
likened completion of HCV treatment to a last step to
recovery.
“You come in here to stop drinking and using drugs; I
don’t want to die no more. I don’t want to go, to live in
a box. I don’t want to eat out of the garbage. I don’t
want to go to jail. I want to change”[12].
Discussion
This review explores ways to improve HCV treatment
adherence among PWID and has implications for scaling
up DAA treatment regimens. Better understanding
PWID in the context of HCV treatment adherence will
be critical for expanding DAA regimens. Several review
papers have examined the social context of HCV treat-
ment among PWID, [10, 43, 44] with a focus on access
to treatment [10]. This review expands the literature by
using a systematic approach (including formal assessment
of study quality), focusing on facilitators of HCV adher-
ence, and considering implications for DAA scale up.
Our findings suggest that integrating HCV treatment
and addiction services will enhance HCV treatment ad-
herence among PWID. Few quantitative studies have
evaluated integration of these services as an intervention
[45, 46]. These studies, though small in sample size, have
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shown promising results for integrated clinics. For ex-
ample, one study showed treatment adherence among
86 % of patients in an integrated clinic, with adherence
defined as completing ≥80 % of treatment regimen [47].
The process of integration ranges from services co-
located in a single clinic [27, 38] to facilitated addiction
service referrals at HCV treatment clinics and may even
include a mix of these [41]. Integration would mitigate
several logistical barriers that PWID commonly encoun-
ter [32, 35]. Addiction treatment and HCV treatment
regimens are both physically [12] and emotionally
demanding, [34] and patients report missing one at the
expense of the other, [12] This problem is minimized
through offering care for both at the same visit. Further-
more, PWID also report feeling more comfortable re-
ceiving care from doctors and nurses experienced in
treating injection drug users, such as in drug treatment
centers [33]. Concerns with integrated clinics include
further linking HCV to intravenous drug use and in-
creasing the stigma of the disease, [37] lack of prepar-
ation by addiction care providers to provide HCV care,
[38] and patient reluctance to fully disclose drug-related
information at the risk of disqualification from addiction
care [48]. However, these concerns are theoretical, and
have not been documented [33]. Similar approaches have
been met with success in the treatment of HIV in PWID
by integrating mental health or substance abuse treatment
services with anti-retroviral treatment (ART) delivery [49].
We found that positive support from clinic staff, espe-
cially peer counselors, facilitated HCV treatment adher-
ence among PWID. Patients stated interferon-based
regimens and side effects were more tolerable when they
felt respected by doctors and nurses [29, 37]. Peer coun-
selors acting as a bridge between patient and provider
help to create a more comfortable setting to share infor-
mation [32]. With regards to HIV treatment for PWID,
peer counseling at the point of ART delivery has been
associated with a 95 % treatment adherence rate among
IDUs [50]. We anticipate that even in the advent of
DAA therapy, peer counseling and positive support from
clinic staff will continue to be an important facilitator of
treatment adherence.
Our findings suggested that integration of HCV treat-
ment services and mental health services facilitated
HCV treatment adherence. Quantitative reviews ad-
dressing this topic evaluated studies using both pharma-
ceutical and behavioral interventions [45, 46] but have
shown inconclusive results. Our qualitative data showed
that patients view depression and mental distress as a
significant barrier to continuing treatment. Individuals
living with HCV have an increased prevalence of mental
illness because of virus-mediated effects, [51] treatment-
related side effects, and comorbidities common among
PWID [16]. Untreated mental health problems in turn
can lead to a vicious cycle of poor adherence because of
low mood, poor concentration and anxiety [16]. Integra-
tion of HCV treatment and mental health services may
improve both SVR and mental health outcomes, [46]
though more research is required. Given hesitation on
the part of some providers to treat individuals with HCV
and ongoing mental health problems, integration of ser-
vices may also help expand access to HCV treatment
among PWID [52].
Moving towards the age of universal DAA treatment
regimens
As DAAs are a relatively new development, the literature
reviewed in our study all dealt with treatment regimens
involving interferons and all of their associated side ef-
fects. While there is a move towards DAAs as the stand-
ard of care (as is the case in the United States, the United
Kingdom, Australia and other high-income countries), we
predict there will still be some time until they are univer-
sally adopted. While price is the most significant barrier
for many countries, other issues such as drug registration
and approval may also delay the process [53].
Limitations
Our study has several limitations. Nine out of the ten
studies examined individuals receiving interferon-based
treatment. The only study including patients on DAA
therapy still included pegIFN + RBV in the triple therapy
regimen [34]. Interferon-free DAA regimens have fewer
side effects, [54] and so our findings directly related to
inability to cope with side effects, withdrawal-like side
effects and injections reminiscent of drug use will be less
of an issue with interferon-free DAA therapy. However,
several of the themes identified are still relevant, includ-
ing the importance of HCV treatment service integra-
tion, nonjudgmental clinic staff, flexible clinic hours, and
an understanding of the PWID identity. Another major
limitation of our study was that all include studies were
conducted in high-income, English-speaking countries,
despite the search being conducted with no language re-
strictions. It is concerning that there is a lack of available
literature on the topic from low- and middle-income
countries. However, this is consistent with the fact that
there are decreased rates of HCV testing and treatment
in these setting as well [55]. While it is difficult to
generalize our findings to lower-income settings with
any certainty, similar reviews conducted on facilitators
and barriers of HIV treatment adherence in developing
and developed countries have found several areas of
overlap. While themes directly relating to access to
treatment and financial difficulties are more prevalent in
developing countries, more patient-centered themes
such as fear of stigma, mistrust of the medical establish-
ment and concurrent substance addiction and mental
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illness remained equally relevant in both developing and
developed countries [56]. We expect that the same
would be true of our findings.
Conclusion
Our review highlights the need for more qualitative re-
search on hepatitis C service delivery among PWID. As
DAA use expands, further qualitative evaluation will be
essential to ensure that HCV service delivery models are
responsive to the unique needs and preferences of
PWID. We anticipate that while some themes we identi-
fied will be less relevant with the gradual phasing out of
interferon-based regimens, many of the core themes that
we uncovered will not change. In particular, the need for
integration of addiction and mental health services
within HCV treatment delivery is unlikely to be affected
by the introduction of DAAs. Some of the evidence
gathered from delivering HIV services to PWID [57]
may be able to inform the development of high quality
HCV services for PWID.
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